Haemophilia is a rare blood clotting disorder, characteristic features of which include extemporaneous and post-traumatic subcutaneous bleeding and mucosal haemorrhages. Genetic deficiency of coagulation factor VIII results in haemophilia A, while deficiency of factor IX leads to haemophilia B. The most common treatment for haemophilia A is administration of recombinant or plasma-derived factor VIII concentrate, to raise the levels of the deficient factor VIII. Tranexamic acid is also used as an anti-fibrinolytic agent that inhibits plasminogen activators present in oral secretion and stabilises the clot. Administration of factor IX is required in haemophilia B. Treatment leads to increased longevity and quality of life for patients. Dental conditions and treatments are more complicated and uncertain in patients with haemophilia due to bleeding risk, thus restorative dental care is of paramount importance for those with haemophilia. The fear of bleeding during treatment procedures is the primary cause of lack of proper dental care for people with haemophilia in countries with limited health care resources. This case report highlights the significance of clinical examination and investigation, and the importance of proper interaction between a haematologist and the periodontist for correct multidisciplinary and uneventful management of periodontal health of a patient with haemophilia.
1. Zaliuniene R, Peciuliene V, Brukiene V, Aleksejuniene J. Hemophilia and oral health. Stomatologija 2014; 16(4): 127-31.
2. Srivastava A, Brewer AK, Mauser Bunschoten EP et al. Treatment Guidelines Working Group. The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1V14.
3. Gupta A, Epstein J B, Cabay RJ. Bleeding disorders of importance in dental care and related patient management. J Can Dent Assoc 2007; 73(1): 77-83.
4. Nickles K, Wohlfeil M, Alesci S, et al. Comprehensive treatment of periodontitis in patients with von Willebrand disease. J Periodontol 2010; 81(10): 1432-40.
5. Durham TM, Hodges ED, Harper J, et al. Management of traumatic oralfacial injury in the hemophiliac patient with inhibitor: case report. Pediatr Dent 1993; 15(4): 282-7.
6. Hidaka N, Maeda K, Kawakami C, et al. Fibrinolytic activity in periodontal disease. The relationship between fibrinolytic activity and severity of periodontal disease. J Periodontol 1981; 52(4): 181-6.
7. Kumar JN, Kumar RA, Varadarajan R, Sharma N. Specialty dentistry for the hemophiliac: is there a protocol in place? Indian J Dent Res 2007; 18(2): 48-54.
8. Anderson JA, Brewer A, Creagh D, Hook, et al. Guidance on the dental management of patients with haemophilia and congenital bleeding disorders. Br Dent J 2013; 215(10): 497-504.
9. Gornitsky M, Hammouda W, Rosen H. Rehabilitation of a hemophiliac with implants: a medical perspective and case report. J Oral Maxillofac Surg 2005; 63(5): 592-7.
10. Franchini M, Rossetti G, Tagliaferri A, et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia 2005; 11(5): 504-9.
11. Vassilopoulos P, Palcanis K. Bleeding disorders and periodontology. Periodontol 2000 2007; 44: 211-23.
12. Lockhart PB, Gibson J, Pond SH, Leitch J. Dental management considerations for the patient with an acquired coagulopathy. Part 2: Coagulopathies from drugs. Br Dent J 2003; 195(9): 495-501.
13. Hay CR, Laurian Y, Verroust F, Preston FE, Kernoff PB. Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy. Blood 1990; 76(5): 882-6.
14. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol 1992; 14(1): 82-7.
15. Mariani G, Kroner B. Immune Tolerance Study Group (ITSG). Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86(11): 1186-93.